FDA blocks Merck's OTC bid for Mevacor

12/13/2007 | Bloomberg1 · Wall Street Journal, The

An FDA advisory panel voted 10-2 to reject Merck & Co.'s third bid to obtain approval for an over-the-counter version of Mevacor. The panel was concerned that patients would not know how to use the cholesterol-lowering drug, which is now only available by prescription.

View Full Article in:

Bloomberg1 · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC